Legal Representation
Attorney
Christina M. Licursi
USPTO Deadlines
Application History
49 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Oct 7, 2025 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Oct 6, 2025 | EX5G | S | SOU EXTENSION 5 GRANTED | Loading... |
| May 21, 2025 | EXT5 | S | SOU EXTENSION 5 FILED | Loading... |
| Oct 6, 2025 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
| May 22, 2025 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Apr 24, 2025 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| Apr 24, 2025 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | Loading... |
| Apr 24, 2025 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED | Loading... |
| Mar 3, 2025 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Nov 26, 2024 | EX4G | S | SOU EXTENSION 4 GRANTED | Loading... |
| Nov 26, 2024 | EXT4 | S | SOU EXTENSION 4 FILED | Loading... |
| Nov 26, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| May 30, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| May 29, 2024 | EX3G | S | SOU EXTENSION 3 GRANTED | Loading... |
| May 29, 2024 | EXT3 | S | SOU EXTENSION 3 FILED | Loading... |
| May 29, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Nov 16, 2023 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Nov 15, 2023 | ASGN | I | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | Loading... |
| Nov 14, 2023 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
| Nov 14, 2023 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
| Nov 14, 2023 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Apr 29, 2023 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Apr 27, 2023 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Apr 27, 2023 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Apr 27, 2023 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Nov 29, 2022 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Oct 17, 2022 | NEWN | I | NEW NOA TO ISSUE | Loading... |
| Jul 26, 2022 | IUCN | S | NOTICE OF ALLOWANCE CANCELLED | Loading... |
| Jul 28, 2022 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| May 31, 2022 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| May 31, 2022 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| May 11, 2022 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Apr 28, 2022 | PREV | O | LAW OFFICE PUBLICATION REVIEW COMPLETED | Loading... |
| Apr 25, 2022 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Apr 21, 2022 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Apr 21, 2022 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Apr 20, 2022 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Apr 18, 2022 | ERFR | I | TEAS REQUEST FOR RECONSIDERATION RECEIVED | Loading... |
| Nov 1, 2021 | GNFN | O | NOTIFICATION OF FINAL REFUSAL EMAILED | Loading... |
| Nov 1, 2021 | GNFR | O | FINAL REFUSAL E-MAILED | Loading... |
| Nov 1, 2021 | CNFR | R | FINAL REFUSAL WRITTEN | Loading... |
| Oct 6, 2021 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Oct 6, 2021 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Oct 6, 2021 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Aug 4, 2021 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Aug 4, 2021 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Aug 4, 2021 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Jul 22, 2021 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Apr 14, 2021 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceutical preparations for gene therapy; pharmaceutical preparations, namely, nucleic acid therapeutics for the treatment of genetic disorders, immune system related diseases and disorders, metabolic diseases and disorders, hematological diseases and disorders, cancer, neurological diseases and disorders, reproductive diseases and disorders, gynecological diseases and disorders, inflammatory diseases and disorders, cardiological diseases and disorders, respiratory diseases and disorders, gastroenterological diseases and disorders, musculoskeletal diseases and disorders, ophthalmological diseases and disorders, and dermatological diseases and disorders; pharmaceutical preparations, namely, RNA therapeutics for the treatment of genetic disorders, immune system related diseases and disorders, metabolic diseases and disorders, hematological diseases and disorders, cancer, neurological diseases and disorders, reproductive diseases and disorders, gynecological diseases and disorders, inflammatory diseases and disorders, cardiological diseases and disorders, respiratory diseases and disorders, gastroenterological diseases and disorders, musculoskeletal diseases and disorders, ophthalmological diseases and disorders, and dermatological diseases and disorders
Class 042
Testing, inspection, research, and development of pharmaceutical preparations for gene therapy
Classification
International Classes
005
042